Reports Q3 revenue $966,000, consensus $3.33M. “We solidified our clinical leadership in sustained release therapy for retinal disease, with DURAVYU now in Phase 3 development in the two largest markets, wet AMD and DME,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint (EYPT). “With topline data from our LUGANO trial expected in mid-2026 and LUCIA to closely follow, we believe we are well-positioned for DURAVYU to be first to file and first to market among all investigational sustained release programs in this indication, positioning DURAVYU at the forefront of innovation.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint price target raised to $33 from $28 at Mizuho
- EyePoint Pharma’s DEXYCU Study: A Potential Game-Changer in Pediatric Cataract Treatment
- EYPT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- EyePoint Pharmaceuticals Raises $141M in Public Offering
- EyePoint reports inducement grants under NASDAQ listing rule